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Approximately 2 million people die of tuberculosis (TB†) each year. The current vaccine,
Bacille Calmette-Gu￩rin (BCG), albeit widely employed, does not protect against adult pul-
monary disease, and new vaccines are urgently needed to reduce the incidence of TB world-
wide. New insights into the cellular and molecular mechanisms that underlie the interactions
between Mycobacterium tuberculosis and its host have been exploited to develop novel
vaccine candidates that recently have entered clinical trials. This review provides a brief
overview of different approaches toward a new vaccination strategy and summarizes major
challenges for the next decade.
introduction
Tuberculosis (TB) is an ancient human
scourge that causes approximately 2 mil-
lion deaths each year [1]. Two billion indi-
viduals worldwide, about one-third of the
human population, are infected with the
causative agent of TB, Mycobacterium tu-
berculosis (M. tuberculosis). Ninety per-
cent  of  infected  individuals  are  latently
infected, i.e., they harbor the pathogen in
its dormant form, whereas the remaining 10
percent suffer from active disease [2]. In
the Western world, the infection is held in
check by an efficient health care system,
while in many regions of the developing
world, resources that are available to pre-
vent, identify, and treat active TB are lim-
ited and in many cases overwhelmed by the
high number of infected patients. In these
regions, TB is a serious obstacle to eco-
nomic development, and new vaccines are
desperately needed to reduce the incidence
of TB in the long term [3].
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date.Here, we will summarize current efforts
to use our understanding of the immune re-
sponse against M. tuberculosis for the ra-
tional design of new vaccines and present an
overview of the major challenges that re-
main to be solved.
tHe immune response AgAinst
M. tuberculosis And eVAsion
strAtegies
After  M.  tuberculosis is  inhaled,  it  is
phagocytosed  by  antigen-presenting  cells
(APCs)  in  the  lung,  such  as  alveolar
macrophages, lung parenchyma macrophages,
and dendritic cells. Subsequently, these cells
elicit local inflammatory responses, leading to
the recruitment of mononuclear cells from the
blood, which in turn become potential targets
for infection [4]. Inside the phagosomal com-
partment, the mycobacteria employ their first
immune evasion strategy as they prevent phago-
some acidification and thus survive within this
compartment [5]. Second, M. tuberculosis ap-
parently can escape into the cytosol and thus
evade phagosomal effector mechanisms [6].
The pathogen is eventually controlled by
granuloma formation, which is the defining
histopathologic hallmark of the disease. The
granuloma, first being an amorphous aggre-
gate of macrophages, neutrophils, and mono-
cytes,  develops  into  a  more  organized
structure with the initiation of an adaptive im-
mune response. Immune cells and a fibrotic
wall surround the granulomas in order to pre-
vent bacterial spreading [7]. In this form, dis-
ease outbreak can be prevented over long
periods of time unless the immune response
weakens. Massive cell death leads to caseation
of the granuloma, and M. tuberculosis can no
longer be enclosed. M. tuberculosis exploits
cell necrosis to leave its host cells and spread,
whereas apoptotic cell death sustains plasma
membrane integrity and thus impedes M. tu-
berculosis exit. Here again, the bacteria ap-
parently have developed an evasion strategy,
since a recent report found that virulent M. tu-
berculosis blocks  apoptosis  by  inhibiting
prostaglandin E2 (PGE2) production [8].
The preponderance of evidence indicates
a crucial role for T cells in the containment of
M. tuberculosis [9]. CD4+ T cells, predomi-
nantly T helper (TH) 1 and TH17 cells, exert
their protective function by the production of
cytokines, including IFNʳ and IL-17, respec-
tively [10,11]. M. tuberculosis-specific CD4+
T lymphocytes are activated by APCs that
have taken up and processed M. tuberculosis-
derived antigens that are presented by MHC
class II molecules. Importantly, the bacteria
have developed a further immune evasion
strategy to interfere with this process, since
they are capable of inhibiting MHC class II
molecule expression and antigen presentation.
This evasion strategy is based on innate im-
mune recognition of the bacteria via Toll-like
receptor 2 (TLR2), indicating that, during the
course of evolution, M. tuberculosishas found
a way to turn the spear and exploit the host’s
innate defense mechanisms to its own advan-
tage [12].
Notably, CD8+ T cells contribute to host
defense, not only by cytokine production, but
also by perforin- and granzyme-mediated cy-
totoxic activity against the pathogen and in-
fected phagocytes. In contrast to CD4+T cells,
it is required for the priming of CD8+ T cells
that APCs take up exogenous antigen and
present it in complex with MHC class I mol-
ecules, a process called cross-presentation
[13]. Remarkably, cross-presentation also is
subject to inhibition through bacterial evasion
strategies that utilize eicosanoid pathways [8].
Furthermore, the involvement of lym-
phocytes in host defense against an infection
leads to the development of a memory re-
sponse that normally rapidly elicits a second-
ary  response  after  re-encounter  of  the
pathogen [14]. In the case of chronic TB,
however,  the  memory  response  must  be
tightly controlled in order to master the deli-
cate tightrope walk between immunopathol-
ogy and host integrity.
Taken together, this brief summary of
the immune response against M. tuberculo-
sis and the evasion strategies employed by
the pathogen already suggests that a suc-
cessful vaccination will be based on efficient
antigen  presentation  and  activation  of  T
cells, as well as the induction of appropriate
memory responses. How new vaccines try
to address these important hallmarks of a
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below.
tHe current VAccine
Bacille  Calmette-Gu￩rin  (BCG),  the
current vaccine for TB, has been used for
decades and about 4 billion individuals have
received the vaccination so far [15]. BCG is
impressive with respect to its low cost and
its high safety [16]. Nonetheless, the vaccine
has several limitations [17]. BCG, albeit
protective  against  severe  childhood  TB,
does not satisfactorily prevent adult pul-
monary disease. The potential reasons for
this failure are multifaceted.
First, exposure to environmental my-
cobacteria, which is common in developing
countries, has been reported to weaken and
shorten the immune response elicited by
BCG and could, therefore, affect the out-
come  of  BCG  vaccination  [18].  Second,
helminth infection is believed to diminish
the efficacy of BCG vaccination because it
favors the development of a TH2 response
and  thereby  weakens  TH1  polarization,
which is induced by the vaccine [19]. While
a TH2 response is an immune response di-
rected against extracellular microbes and
mainly  driven  by  interleukin-4,  TH1  re-
sponses  are  IFNʳ-mediated  responses
against intracellular pathogens and thus ben-
eficial for host defense against M. tubercu-
losis. Third, recent discussions suggest that
some individuals might clear BCG before a
protective and sustained immune response
can develop.
Moreover, we are only beginning to un-
derstand  how  numerous  human  genetic
polymorphisms are linked with susceptibil-
ity to TB and with different outcomes of
BCG vaccinations between individuals [20].
Different M. tuberculosis lineages seem to
have adapted to distinct host populations
during evolution, and, hence, the degree of
virulence/persistence of M. tuberculosis de-
pends in part on the genetic background of
the host [21].
It has been known for some time that
repeated BCG vaccination can have detri-
mental effects (“Koch phenomenon”). Re-
cently, it has been revealed that repeated ex-
posure to mycobacterial antigen, especially
in the form of BCG vaccination after M. tu-
berculosis infection, promotes IL-17-depen-
dent immunopathologies of the lung [22]. In
this study, repetitive vaccination was found
to cause abundant cytokine expression and
recruitment of granulocytes to infected tis-
sue. Apparently, repeated exposure to anti-
gen  disturbs  the  homeostatic  balance
between  disease  containment  and  im-
munopathology.
Many of these problems, however, are
not BCG-specific and have important impli-
cations for the design of effective vaccines
against M. tuberculosis.
new VAccine cAndidAtes
Considering that about 2 billion humans
are presumably infected with M. tuberculo-
sis, with only 10 percent developing active
disease, it is obvious that vaccination strate-
gies follow two different approaches: pre-
exposure vaccination in order to prevent
disease in individuals that have so far not en-
countered M. tuberculosis versus post-expo-
sure  vaccination  that  aims  at  inhibiting
disease outbreak in individuals that are al-
ready infected. Up to now, the majority of
novel candidates belongs to the first group.
According to their strategies of how to sup-
port the immune system, four categories can
be distinguished.
The first category follows the approach
to improve the current BCG vaccine through
recombinant (r)BCG strains. The two major
representatives of this group are rBCG30,
which is a BCG strain overexpressing the
immunodominant M. tuberculosis antigen
85B, and rBCGʔUreC:Hly, which is defi-
cient in urease (with the consequence of an
acidic  pH  in  vaccine-containing  phago-
somes) and expresses listeriolysin (which
enables it to perforate the phagosomal mem-
brane) [23]. Both candidates have success-
fully completed Phase I clinical trials. The
mechanism underlying their function is im-
proved antigen presentation, which in turn
leads to a stronger T cell response. Most im-
portantly, their safety in preclinical tests was
211 Thaiss: Chances and challenges with new tuberculosis vaccinesimproved in comparison to BCG, especially
in immunocompromised mice. As potential
BCG replacements, these candidates will
function as pre-exposure priming vaccines.
In contrast, the second category of vac-
cine candidates is considered more for het-
erologous prime-boost strategies, with BCG
or rBCG as the prime. The first subgroup in-
cludes viral vectors that express immun-
odominant M. tuberculosis antigens for the
initiation of strong lymphocyte responses.
MVA85A is a modified vaccinia strain [24],
while AERAS-402 and AdAg85A make use
of adenoviruses that are incapable of repli-
cation, with the advantage of a strong lung
tropism that leads to an increased expression
of immunodominant antigen at the site of
mycobacterial entry [25,26]. It may be prob-
lematic, however, for their application in hu-
mans, if neutralizing antibodies against the
viral vectors in the recipient clear the viral
particles before they have had a chance to
exert an immunostimulatory effect.
The second subgroup for heterologous
prime-boost comprises fusion proteins of
immunodominant antigens, again with the
aim of mounting strong immune responses
against immunologically important M. tu-
berculosis antigens.  To  ensure  immuno-
genicity, antigenicity has to be combined
with adjuvanticity, and, hence, these vaccine
candidates are administered as protein adju-
vant formulations. Hybrid-1 includes the
antigens  85B  and  ESAT-6  and  has  been
combined with adjuvants IC-31 (a TLR9 ag-
onist plus polycationic peptide) and CAF01
(a mycobacterial cell wall component deliv-
ered in cationic liposomes). IC-31 is also
used in combination with HyVac4/AERAS-
404, which also includes the antigen 85B,
but together with TB10.4 instead of ESAT-6
[27]. In addition, the antigens Rv1196 and
Rv0125, whose function is poorly under-
stood, are combined in the M72 vaccine that
is supplemented with adjuvants AS01 or
AS02 (which exert a TLR4-agonistic effect)
[28].
Finally, the inactivated mycobacteria M.
vaccae and the semi-purified M. tuberculo-
sis fragments RUTI are considered for ap-
plication after infection, more precisely as
therapeutic vaccinations that could poten-
tially synergize with chemotherapy [29,30].
M. vaccae is a whole-cell vaccine that con-
sists of heat-inactivated environmental my-
cobacterial  saprophytes.  This  vaccine  is
thought to mount a protective immune re-
sponse by providing cross-reactive antigens.
RUTI comprises detoxified and fragmented
M. tuberculosis components carried in lipo-
somes. The rationale behind both strategies
takes advantage of the bactericidal effects of
chemotherapy in order to eliminate growing
bacteria and subsequently reduce the likeli-
hood of regrowth of remaining pathogens
through the elicitation of a strong cellular
immune response.
new Hopes And mAjor 
obstAcles 
With the vaccine candidates described
above, the end of the pipeline is still far from
being reached. Instead, ongoing basic re-
search that aims at further vaccine improve-
ment  has  revealed  mechanisms  that
potentially can be exploited for vaccine con-
structs. For instance, efforts to improve the
efficacy and safety of live vaccine strains in-
clude the deletion of anti-apoptotic genes,
the modification of DNA repair molecules,
and the generation of auxotrophic strains
[31]. These strategies still allow the vaccine
to replicate and survive for a limited time
period (as long as necessary for initiating
sufficient immunity), but decrease the risk
of dissemination by restricting its life time
to a minimum.
All of the vaccine candidates described
above aim at preventing primary TB or re-
activation of latent TB. However, the ulti-
mate goal is to achieve sterile eradication,
i.e., the complete elimination of M. tubercu-
losis from the host after infection. The opti-
mal  future  vaccination  scenario  could
conceivably consist of the following steps:
First, soon after birth, a highly potent
BCG replacement will be given. The two
currently evaluated candidates are promis-
ing, and new approaches are on their way, in-
cluding AERAS-rBCG, which combines the
strategies of rBCG30 and rBCGʔUreC:Hly
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lacks the virulence factors phoP and fadD26
[33].
Booster vaccines ― either in the form
of viral vectors or protein/adjuvant formula-
tions ― will then be given repeatedly, ide-
ally comprising a whole array of antigens
from different stages of the M. tuberculosis
life cycle. Thus, boosters given during in-
fancy should reflect the profile of antigens
associated  with  the  metabolically  active
state, while for adults, it might be an advan-
tage to include dormancy antigens. Such an
optimally tailored vaccination, however, re-
mains a major aim of current and future re-
search.
Another vision for further development
aims at improving the antibody response
against M. tuberculosis, with a special focus
on pre-existing antibodies that are available
quickly enough to opsonize the mycobacte-
ria briefly after their entry into the lung.
Tremendous progress toward prevention of
the disease would be achieved if antibodies
could target M. tuberculosis to phagocytic
Fc receptors and thereby strongly facilitate
uptake  and  subsequent  killing  of  the
pathogen by activated macrophages. More-
over, efficient phagocytosis of mycobacte-
ria that enter the alveolar system of the lung
would prevent the infection of “bystander”
cells, such as epithelial cells or freshly re-
cruited non-professional phagocytes, which
are less efficient in clearing the pathogen
and can be used by M. tuberculosis as a
niche to escape elimination.
What are the main roadblocks for fur-
ther development and assessment of current
vaccine candidates? First, the time needed
for clinical evaluation is critically depend-
ent on reliable biomarkers that allow for the
distinction between non-infected individu-
als, latently infected subjects, and patients
with active disease [34]. Optimally, a biosig-
nature ― based on data from transcriptome,
proteome, and metabolome analysis ― will
be able to predict the clinical endpoint of
disease outbreak [35]. Current diagnostic
tests mainly focus on IFNʳ production by
peripheral lymphocytes, but new indicators
are on their way, potentially including dif-
ferent  cytokines  and  antigens  associated
with dormant and active M. tuberculosis
[36].
Second, suitable animal models are cru-
cial for determining the effectiveness of new
vaccine  candidates  and  evaluating  their
function in various circumstances, including
immunodeficient recipients. The mouse as
the most widely used model to study disease
has a certain limitation insofar as it does not
reflect the full spectrum of granuloma for-
mation  upon  M.  tuberculosis infection.
However,  various  genetically  modified
mouse strains allow the analysis of media-
tors that participate in the immune response
and the determination of factors that are crit-
ical for vaccine-induced immunity. Very re-
cently,  mice  deficient  in  nitric  oxide
synthase 2 have been reported to manifest
human-like granumolas after dermal infec-
tion with M. tuberculosis [37]. The spectrum
of  granulomas  is  found  in  Guinea  pigs,
where they show a similar composition of
cells to humans. TB in nonhuman primates
resembles human disease, but cost and ethi-
cal  considerations  are  major  hurdles  for
broad application. Nonetheless, the lack of
an optimal animal model still remains a bar-
rier for current efforts to test vaccine effica-
cies.
conclusion
After decades of stagnancy in TB re-
search, the past 10 years have shown con-
siderable progress in our understanding of
the interaction between M. tuberculosis and
its host, and this understanding has lead to
the development of about a dozen vaccine
candidates that are currently evaluated in
clinical trials. There are not many fields of
biomedical research in which science po-
tentially can contribute to such a high extent
to socioeconomic development in numerous
countries as is the case in the ongoing quest
against current pandemics. Incentives must
be created for researchers to tackle the most
urgent roadblocks that still thwart an effi-
cient prevention and treatment of the major
infectious diseases, many of which are gen-
erally considered both preventable and cur-
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global open access, partnerships between
public, philanthropic, and private institu-
tions can lay the foundation for improved
development and clinical evaluation of new
diagnostics, drugs, and vaccines.
In the development of a new vaccine
against TB, the first steps have been taken,
as  outlined  in  this  article.  Nonetheless,
major challenges remain, and both scientific
and financial investments will prove pivotal
for further substantial progress in the com-
ing years, with the ultimate goal to create a
strategy that allows for prevention of M. tu-
berculosis infection or sterile eradication of
M. tuberculosis.
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